Drug policy · Rare disease
The orphan drug market was a policy choice, and Britain shows what the alternative looked like
Save this development or follow its topic to track what changes.
Short answer
US orphan drug policy settled on market exclusivity through specific political contingencies, while Britain pursued the same end through state licensing.
What happened
Huyard traces how the 1983 US Orphan Drug Act arrived at market exclusivity and tax credits, against Britain's Medicines Act route of named-patient supply and state product licences. Patient-group visibility, generic-industry politics and FDA insistence on unchanged safety standards together locked in the market-based American model — the one that later produced the pricing problems now treated as intrinsic to rare-disease medicine.
Why it matters
When a policy has been in place for forty years its mechanism starts to look like a law of nature, and arguments about orphan drug pricing usually assume exclusivity is the price of having the drugs at all. A documented alternative that existed at the same moment converts that assumption into a decision with authors and reasons.
Evidence
- Study type
- Policy history from legislative and regulatory records with participant interviews
- Sample
- US and British orphan drug policy from the 1970s onward; interviews with participants in the process
- Journal
- Social History of Medicine · peer reviewed
- Replication
- Not assessed in this corpus; the comparative claim rests on documented parallel policy paths
- Limitations
- Interviews cover people who made the policy, not patients living under it. The study does not price current orphan drugs or counterfactually estimate approvals without the Act.
What this connects to
Sources
The one study this explanation is built from, by the role each plays. Every source links to PaperFren’s explanation of it and to the original paper.
Primary study
- How the US made orphan drugs a market
From Congressional hearings and interviews, Mikami shows the 1983 Orphan Drug Act’s market incentives were a contingent American choice, not the only way to supply rare-disease drugs.
What it does not showLimitations
It does not measure today’s orphan-drug prices or prove how many 350 post-1983 approvals would have appeared without the Act; interviews cover participants, not patients living with current access barriers.
PaperFren explanationStudy with cards and a quizOriginal paper (DOI)cc by
Before
Orphan drug incentives are typically discussed as an economic necessity: without exclusivity, the argument runs, no firm would develop treatments for small populations.
Now
The mechanism was contested and contingent, and a state-licensing alternative was operating in parallel. The paper does not measure today's orphan drug prices or estimate how many of the 350-plus post-1983 approvals would have appeared without the Act.